{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:15:51Z","timestamp":1782882951105,"version":"3.54.5"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejim.2022.06.015","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:30:05Z","timestamp":1655857805000},"page":"23-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the \"Spike effect\""],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4925-7985","authenticated-orcid":false,"given":"Fabio","family":"Angeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9877-0702","authenticated-orcid":false,"given":"Gianpaolo","family":"Reboldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Trapasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8443-5316","authenticated-orcid":false,"given":"Martina","family":"Zappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Spanevello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4135-8936","authenticated-orcid":false,"given":"Paolo","family":"Verdecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2022.06.015_bib0001","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/HYPERTENSIONAHA.120.15353","article-title":"COVID-19: ACE2 centric infective disease?","volume":"76","author":"Verdecchia","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2022.06.015_bib0002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2020.04.037","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection","volume":"76","author":"Verdecchia","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0003","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2021.09.007","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection: one year later","volume":"93","author":"Angeli","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0004","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/HJH.0000000000002859","article-title":"SARS-CoV-2 infection and ACE2 inhibition","volume":"39","author":"Angeli","year":"2021","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2022.06.015_bib0005","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0006","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fpubh.2020.00152","article-title":"Gender differences in patients with COVID-19: focus on severity and mortality","volume":"8","author":"Jin","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.ejim.2022.06.015_bib0007","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fpubh.2020.00418","article-title":"Racial and gender-based differences in COVID-19","volume":"8","author":"Kopel","year":"2020","journal-title":"Front Public Health"},{"key":"10.1016\/j.ejim.2022.06.015_bib0008","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejim.2021.04.007","article-title":"Joint effect of heart failure and coronary artery disease on the risk of death during hospitalization for COVID-19","volume":"89","author":"Angeli","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0009","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/all.14657","article-title":"Risk factors for severe and critically ill COVID-19 patients: a review","volume":"76","author":"Gao","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.ejim.2022.06.015_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108346","article-title":"Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: a meta-analysis","volume":"166","author":"Guo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ejim.2022.06.015_bib0011","doi-asserted-by":"crossref","DOI":"10.4081\/monaldi.2020.1372","article-title":"Severity of COVID-19: the importance of being hypertensive","volume":"90","author":"Angeli","year":"2020","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1016\/j.ejim.2022.06.015_bib0012","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejim.2020.06.015","article-title":"Electrocardiographic features of patients with COVID-19 pneumonia","volume":"78","author":"Angeli","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0013","doi-asserted-by":"crossref","first-page":"H1080","DOI":"10.1152\/ajpheart.00215.2020","article-title":"Letter to the editor: angiotensin-converting enzyme 2: an ally or a trojan horse? Implications to SARS-CoV-2-related cardiovascular complications","volume":"318","author":"Abassi","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0014","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2022.06.015_bib0015","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/CIRCULATIONAHA.120.047049","article-title":"Angiotensin converting enzyme 2: a double-edged sword","volume":"142","author":"Wang","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2022.06.015_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2021.04.019","article-title":"SARS-CoV-2 vaccines: lights and shadows","volume":"88","author":"Angeli","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0017","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00018-006-6317-y","article-title":"Prolyl endopeptidases","volume":"64","author":"Gass","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ejim.2022.06.015_bib0018","doi-asserted-by":"crossref","first-page":"C945","DOI":"10.1152\/ajpcell.00346.2012","article-title":"Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry","volume":"304","author":"Grobe","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0019","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00004872-199107000-00008","article-title":"Evidence that prolyl endopeptidase participates in the processing of brain angiotensin","volume":"9","author":"Welches","year":"1991","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2022.06.015_bib0020","doi-asserted-by":"crossref","first-page":"F1583","DOI":"10.1152\/ajprenal.00087.2012","article-title":"Enzymatic processing of angiotensin peptides by human glomerular endothelial cells","volume":"302","author":"Velez","year":"2012","journal-title":"Am J Physiol Ren. Physiol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/HYPERTENSIONAHA.119.14071","article-title":"Ang II (Angiotensin II) conversion to angiotensin-(1-7) in the circulation Is POP (Prolyloligopeptidase)-dependent and ACE2 (Angiotensin-converting enzyme 2)-independent","volume":"75","author":"Serfozo","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2022.06.015_bib0022","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1161\/01.HYP.4.2.178","article-title":"Brain endo-oligopeptidase B: a post-proline cleaving enzyme that inactivates angiotensin I and II","volume":"4","author":"Greene","year":"1982","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2022.06.015_bib0023","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/0024-3205(93)90108-F","article-title":"A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11","volume":"52","author":"Welches","year":"1993","journal-title":"Life Sci"},{"key":"10.1016\/j.ejim.2022.06.015_bib0024","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1016\/S0021-9258(17)34557-X","article-title":"Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney","volume":"253","author":"Odya","year":"1978","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejim.2022.06.015_bib0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.brainres.2013.10.031","article-title":"Prolyl carboxypeptidase mRNA expression in the mouse brain","volume":"1542","author":"Jeong","year":"2014","journal-title":"Brain Res"},{"key":"10.1016\/j.ejim.2022.06.015_bib0026","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1053\/j.gastro.2020.05.034","article-title":"Associations between angiotensin-converting enzyme inhibitors and angiotensin II receptor blocker use, gastrointestinal symptoms, and mortality among patients with COVID-19","volume":"159","author":"Tan","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2022.06.015_bib0027","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2012-10-460360","article-title":"Prolylcarboxypeptidase promotes angiogenesis and vascular repair","volume":"122","author":"Adams","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2022.06.015_bib0028","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbrc.2010.12.036","article-title":"Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase","volume":"405","author":"Chajkowski","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ejim.2022.06.015_bib0029","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00109-017-1513-9","article-title":"Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II","volume":"95","author":"Maier","year":"2017","journal-title":"J Mol Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0030","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.biocel.2008.02.022","article-title":"Prolylcarboxypeptidase: a cardioprotective enzyme","volume":"41","author":"Mallela","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0031","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11906-009-0032-7","article-title":"Hypertension and the bradykinin system","volume":"11","author":"Sharma","year":"2009","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ejim.2022.06.015_bib0032","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1871525713666150911112916","article-title":"Prolylcarboxypeptidase gene expression in the heart and kidney: effects of obesity and diabetes","volume":"13","author":"Tabrizian","year":"2015","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.ejim.2022.06.015_bib0033","doi-asserted-by":"crossref","first-page":"B792","DOI":"10.1093\/gerona\/58.9.B792","article-title":"Effect of aging on rat tissue peptidase activities","volume":"58","author":"Agirregoitia","year":"2003","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.ejim.2022.06.015_bib0034","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1373\/clinchem.2011.179291","article-title":"Plasma prolylcarboxypeptidase (angiotensinase C) is increased in obesity and diabetes mellitus and related to cardiovascular dysfunction","volume":"58","author":"Xu","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejim.2022.06.015_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197603","article-title":"Prolyl carboxypeptidase activity in the circulation and its correlation with body weight and adipose tissue in lean and obese subjects","volume":"13","author":"Kehoe","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2022.06.015_bib0036","first-page":"547","article-title":"The bariatric surgery patient\u2013nutrition considerations","volume":"42","author":"Shannon","year":"2013","journal-title":"Aust Fam Physician"},{"key":"10.1016\/j.ejim.2022.06.015_bib0037","doi-asserted-by":"crossref","first-page":"15078","DOI":"10.1038\/s41598-018-33523-7","article-title":"Pro-opiomelanocortin and its processing enzymes associate with plaque stability in human atherosclerosis - tampere vascular study","volume":"8","author":"Rinne","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejim.2022.06.015_bib0038","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/157488410791110742","article-title":"The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade","volume":"5","author":"Chrysant","year":"2010","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0039","first-page":"321","article-title":"ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus","volume":"21","author":"Verdecchia","year":"2020","journal-title":"G Ital Cardiol (Rome)"},{"key":"10.1016\/j.ejim.2022.06.015_bib0040","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1097\/HJH.0000000000002469","article-title":"Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus","volume":"38","author":"Verdecchia","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2022.06.015_bib0041","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ajpath.2021.04.010","article-title":"ACE2 down-regulation may act as a transient molecular disease causing RAAS dysregulation and tissue damage in the microcirculatory environment among COVID-19 patients","volume":"191","author":"Ramos","year":"2021","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0042","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3389\/fimmu.2020.01472","article-title":"Intoxication with endogenous angiotensin II: a COVID-19 hypothesis","volume":"11","author":"Sfera","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0043","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14656566.2021.1990264","article-title":"Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients","volume":"23","author":"Angeli","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejim.2022.06.015_bib0044","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1056\/NEJMc2030446","article-title":"RAAS inhibitors and risk of COVID-19","volume":"383","author":"Angeli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0045","first-page":"15","article-title":"Renin angiotensin system blockers and risk of mortality in hypertensive patients hospitalized for COVID-19: an Italian registry","volume":"9","author":"Angeli","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.ejim.2022.06.015_bib0046","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s13054-020-03015-0","article-title":"Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients","volume":"24","author":"Wu","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.ejim.2022.06.015_bib0047","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci"},{"issue":"0658","key":"10.1016\/j.ejim.2022.06.015_bib0048","article-title":"Ageing, ACE2 deficiency and bad outcome in COVID-19","author":"Angeli","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0049","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejim.2021.10.006","article-title":"Electrocardiographic features of patients with COVID-19: one year of unexpected manifestations","volume":"95","author":"Angeli","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0050","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6731093","article-title":"Age-associated changes in the vascular renin-angiotensin system in mice","volume":"2016","author":"Yoon","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.ejim.2022.06.015_bib0051","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.lfs.2005.09.038","article-title":"Age- and gender-related difference of ACE2 expression in rat lung","volume":"78","author":"Xie","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.ejim.2022.06.015_bib0052","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13168","article-title":"Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation","volume":"19","author":"Chen","year":"2020","journal-title":"Aging Cell"},{"key":"10.1016\/j.ejim.2022.06.015_bib0053","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nature24265","volume":"550","author":"Tukiainen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejim.2022.06.015_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113825","article-title":"Downregulation of spinal angiotensin converting enzyme 2 is involved in neuropathic pain associated with type 2 diabetes mellitus in mice","volume":"174","author":"Yamagata","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108132","article-title":"COVID-19, diabetes mellitus and ACE2: the conundrum","volume":"162","author":"Pal","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ejim.2022.06.015_bib0056","first-page":"426021","article-title":"Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2 and heparan sulfate","volume":"2021","author":"Prieto-Fern\u00e1ndez","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.ejim.2022.06.015_bib0057","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","article-title":"Role of the ACE2\/angiotensin 1-7 axis of the renin-angiotensin system in heart failure","volume":"118","author":"Patel","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2022.06.015_bib0058","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejim.2022.06.015_bib0059","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1161\/01.RES.0000205761.22353.5f","article-title":"Angiotensin-converting enzyme II in the heart and the kidney","volume":"98","author":"Danilczyk","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2022.06.015_bib0060","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1161\/CIRCHEARTFAILURE.108.840124","article-title":"Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction","volume":"2","author":"Kassiri","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2022.06.015_bib0061","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/01.HYP.0000205833.89478.5b","article-title":"Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II","volume":"47","author":"Yamamoto","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2022.06.015_bib0062","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3389\/fimmu.2015.00387","article-title":"The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis","volume":"6","author":"Waumans","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114738","article-title":"The C-terminal cleavage of angiotensin II and III is mediated by prolyl carboxypeptidase in human umbilical vein and aortic endothelial cells","volume":"192","author":"De Hert","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0064","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cca.2022.03.005","article-title":"Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients","volume":"531","author":"Bracke","year":"2022","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ejim.2022.06.015_bib0065","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.hlc.2020.11.008","article-title":"The counter regulatory axis of the lung renin-angiotensin system in severe COVID-19: pathophysiology and clinical implications","volume":"30","author":"Triposkiadis","year":"2021","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.ejim.2022.06.015_bib0066","doi-asserted-by":"crossref","first-page":"n699","DOI":"10.1136\/bmj.n699","article-title":"COVID-19: European countries suspend use of oxford-AstraZeneca vaccine after reports of blood clots","volume":"372","author":"Wise","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2022.06.015_bib0067","unstructured":"Joint CDC and FDA Statement on Johnson & Johnson COVID-19 Vaccine. https:\/\/www.fda.gov\/news-events\/press-announcements\/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine (Last access on date April 14, 2021 )."},{"issue":"22","key":"10.1016\/j.ejim.2022.06.015_bib0068","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ejim.2022.06.015_bib0069","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0070","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jamainternmed.2021.5511","article-title":"Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older","volume":"181","author":"Simone","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0071","first-page":"e24084","article-title":"Comorbidities and symptomatology of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-related myocarditis and SARS-CoV-2 vaccine-related myocarditis: a review","volume":"14","author":"Cushion","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.ejim.2022.06.015_bib0072","article-title":"COVID-19 vaccine-induced myocarditis: case report with literature review","volume":"15","author":"Nassar","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.ejim.2022.06.015_bib0073","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.carrev.2021.08.012","article-title":"Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: a case report and literature review","volume":"38","author":"Sulemankhil","year":"2022","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0074","article-title":"Acute fulminant myocarditis After ChAdOx1 nCoV-19 vaccine: a case report and literature review","volume":"9","author":"Wu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0075","article-title":"Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature","volume":"12","author":"Lane","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejim.2022.06.015_bib0076","first-page":"150","article-title":"Blood pressure increase following COVID-19 vaccination: a systematic overview and meta-analysis","volume":"9","author":"Angeli","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.ejim.2022.06.015_bib0077","first-page":"10","article-title":"Hypertension after COVID-19 vaccination","volume":"23","author":"Angeli","year":"2022","journal-title":"G Ital Cardiol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0078","doi-asserted-by":"crossref","unstructured":"Watanabe Y., Mendonca L., Allen E.R., Howe A., Lee M., Allen J.D., Chawla H., Pulido D., Donnellan F., Davies H., Ulaszewska M., Belij-Rammerstorfer S., Morris S., Krebs A.S., Dejnirattisai W., Mongkolsapaya J., Supasa P., Screaton G.R., Green C.M., Lambe T., Zhang P., Gilbert S.C. and Crispin M. Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19\/AZD1222 vaccine. BioRxiv. 2021.","DOI":"10.1101\/2021.01.15.426463"},{"key":"10.1016\/j.ejim.2022.06.015_bib0079","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2022.06.015_bib0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13045-020-00954-7","article-title":"SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0081","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejim.2021.06.013","article-title":"Blood pressure increase after Pfizer\/BioNTech SARS-CoV-2 vaccine","volume":"90","author":"Zappa","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0082","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.109.138420","article-title":"Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension","volume":"55","author":"Wysocki","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2022.06.015_bib0083","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajog.2006.01.079","article-title":"Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia","volume":"195","author":"Wang","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejim.2022.06.015_bib0084","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1182\/blood-2010-11-318527","article-title":"Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis","volume":"117","author":"Adams","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2022.06.015_bib0085","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1161\/HYPERTENSIONAHA.110.155051","article-title":"Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells","volume":"56","author":"Zhu","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2022.06.015_bib0086","series-title":"Proceedings of the United States Advisory Committee on Immunization Practices (US ACIP) COVID-19 vaccines work group conference","article-title":"COVID-19 mRNA vaccines in adolescents and young adults: benefit-risk discussion","author":"Wallace","year":"2021"},{"key":"10.1016\/j.ejim.2022.06.015_bib0087","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0088","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa2107051","article-title":"Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia","volume":"385","author":"Bourguignon","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0089","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical Features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2022.06.015_bib0090","unstructured":"https:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2021-12-16\/02-COVID-See-508.pdf (Accessed on May 31, 2022)."},{"key":"10.1016\/j.ejim.2022.06.015_bib0091","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1016\/j.vaccine.2021.09.060","article-title":"Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021","volume":"39","author":"Tran","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ejim.2022.06.015_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antivir. Res"},{"key":"10.1016\/j.ejim.2022.06.015_bib0093","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00018-020-03580-1","article-title":"Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies","volume":"78","author":"Mercurio","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ejim.2022.06.015_bib0094","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/01.HYP.19.6.692","article-title":"In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats","volume":"19","author":"Yamamoto","year":"1992","journal-title":"Hypertension"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620522002345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620522002345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:37:06Z","timestamp":1760607426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620522002345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":94,"alternative-id":["S0953620522002345"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2022.06.015","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the \"Spike effect\"","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2022.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}